{"entity":{"id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","aka":[],"tldr":"A phase 2 trial of ivonescimab in lung cancer, run by Shaodong Hong, not yet recruiting.","summary":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC is a phase 2, interventional study registered as NCT07819591 by Shaodong Hong, with a registry enrolment figure of 47 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-01. Interventions recorded: Paclitaxel Polymeric Micelles; Ivonescimab. Conditions listed: SCLC, Recurrent. Primary outcome: Outcome Objective Response Rate (ORR) assessed by RECIST v1.1. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed relapsed small-cell lung cancer after failure of platinum-based chemotherapy and PD-1/PD-L1 monoclonal antibody treatment\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07819591","url":"https://clinicaltrials.gov/study/NCT07819591"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["antiangiogenic","bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07819591","phase":"2","setting":"A Phase II Study of Paclitaxel Polymeric Micelles Combined With Ivonescimab in Patients With Recurrent or Refractory Small Cell Lung Cancer After Failure of Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Therapy","sponsor":"Shaodong Hong","enrolled":47,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07819591/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}